Core Insights - Blood lipid management is crucial for preventing cardiovascular diseases and is a significant public health issue, requiring innovative approaches and multi-strategy collaboration [1][2][3] Group 1: Importance of Blood Lipid Management - Effective blood lipid management is essential for cardiovascular disease prevention, as poor lipid control can lead to serious conditions like myocardial infarction and stroke [2][4] - There is a low awareness, treatment, and control rate among patients with lipid abnormalities in China, indicating many are at high risk without symptoms [2][3] Group 2: Technological Integration - The integration of modern technology with healthcare is transforming traditional treatment models, making cardiovascular disease prevention more accessible [2][3] - Wearable devices and AI can enhance the monitoring and analysis of lipid levels, improving patient adherence to treatment and shifting from episodic to continuous intervention [3][4] Group 3: Collaborative Treatment Approaches - Joint treatment strategies are becoming a key focus in lipid management, supported by evidence that lower cholesterol levels reduce cardiovascular disease risk [4][5] - A combination of statins and cholesterol absorption inhibitors is recommended to achieve better lipid control while minimizing side effects associated with high doses of single medications [4][5] Group 4: Essential Medicines and Local Evidence - The basic drug list is crucial for ensuring access to essential medications, and there is a push to expand this list to include more combination therapies [6][7] - Emphasizing local evidence in clinical trials for new drugs is vital for ensuring their effectiveness and safety for the Chinese population [7][8] - A collaborative approach involving research, policy, and clinical practice is necessary to enhance the effectiveness of lipid management and ensure that innovative treatments benefit patients [7][8]

Core Insights - The company, Eurofins, emphasizes its commitment to the Chinese market with the guiding principle of "Establishing China, Benefiting China, and Enriching the World" [1][10] - Eurofins has been actively participating in the China International Import Expo (CIIE) for four consecutive years, viewing it as a vital platform for connecting with potential partners and expanding collaboration [2][10] - The company is focusing on increasing investments in China, particularly in innovative drug development and local partnerships to enhance its product pipeline [3][5][10] Investment Strategy - Eurofins plans to deepen its exploration of early-stage innovative drug assets in China, recognizing the high value of Chinese innovation in the pharmaceutical sector [2][5] - The company has already established a collaboration project and is actively seeking local partners in nine therapeutic areas to drive commercialization in the Chinese market [3][5] Product Development - Eurofins is set to launch a new lipid-lowering combination drug in China by July 2024, further expanding its product offerings in the cardiovascular health sector [6][10] - The company has a strong historical presence in lipid management, having introduced several first-in-class products to address unmet medical needs in this area [6][7] Market Challenges - Despite high awareness of hypertension and diabetes, awareness of dyslipidemia remains low in China, with only 11.7% of adults aware of their lipid levels, leading to a significant treatment gap [7][10] - Eurofins is working to improve the accessibility of quality products through collaborations with various healthcare institutions and enhancing the capabilities of healthcare professionals [7][9] Future Outlook - The company aims to explore more collaborations in areas affecting family health, including women's health and chronic diseases, while adapting to the evolving Chinese market [10] - Eurofins is committed to leveraging the CIIE as a key platform to showcase its health solutions and contribute to the high-quality development of China's population [10]

Core Insights - The article emphasizes the increasing prevalence of dyslipidemia among adults in China, with a reported rate of 35.6% in individuals aged 18 and above as of 2018, highlighting the need for early intervention in blood lipid management [6][8]. Summary by Sections Dyslipidemia Prevalence - Dyslipidemia includes conditions such as hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, and low high-density lipoprotein cholesterol [6]. - The article points out that dyslipidemia often has no early symptoms, yet it can lead to significant vascular damage over time, increasing the risk of atherosclerotic cardiovascular diseases [6]. Importance of Early Intervention - Recent research published in *Nature* suggests that the prevention of atherosclerosis should begin earlier in life, particularly focusing on blood lipid management in children and adolescents [6][8]. - The study conducted by the University of Cambridge indicates that intermittent high-fat diets from a young age significantly increase the risk of atherosclerosis compared to those who only consume high-fat diets later in life [8][9]. Research Findings - The findings from the "Young Finnish Cardiovascular Risk Study" show that individuals with elevated cholesterol levels in childhood have more severe atherosclerotic plaques in adulthood [8][9]. - The research indicates that early cholesterol elevation is closely linked to the incidence and severity of carotid atherosclerosis in middle age [9]. Mechanisms of Atherosclerosis - The study suggests that macrophages, which normally help clear damaged cells and cholesterol, have their gene expression altered by early cholesterol elevation, reducing their protective function [9]. - Intermittent cholesterol elevation, often due to fluctuating dietary habits, may lead to greater damage and increased heart disease risk, particularly in patients who do not adhere to medication regimens [9][11]. Additional Research - A concurrent study from Paris Descartes University also found that intermittent high-fat diets accelerate atherosclerosis more than continuous high-fat diets, indicating a need for consistent dietary management [11].

Core Insights - The article emphasizes the increasing prevalence of dyslipidemia among adults in China, with a reported rate of 35.6% in individuals aged 18 and above as of 2018, highlighting the need for early intervention in blood lipid management [6][8]. Group 1: Health Risks and Findings - Dyslipidemia often presents no early symptoms, yet it can lead to significant vascular damage over time, increasing the risk of atherosclerotic cardiovascular diseases [6]. - Recent research suggests that the prevention of atherosclerosis should begin earlier in life, particularly focusing on the dietary habits of children and adolescents [6][9]. - A study conducted by Cambridge University found that young mice exposed to intermittent high-fat diets exhibited a significantly higher risk of atherosclerosis compared to those that were only exposed in later life [8][9]. Group 2: Research Implications - The findings indicate a strong correlation between elevated cholesterol levels in early life and the severity of atherosclerotic plaques in middle age [9]. - The research identified that early cholesterol elevation alters the gene expression of macrophages, which are crucial for clearing damaged cells and cholesterol, thereby weakening their protective function [9]. - Intermittent spikes in cholesterol levels, often due to dietary fluctuations, may pose greater risks than sustained high cholesterol, as seen in patients who irregularly take statins [9][11]. Group 3: Additional Studies - A concurrent study from Paris University also confirmed that intermittent high-fat diets accelerate atherosclerosis more than continuous high-fat diets, indicating a need for consistent dietary management [11].

Core Viewpoint - High blood lipid levels are a common chronic cardiovascular disease that is often misunderstood, leading to mismanagement of blood lipid levels and health risks [1] Misunderstandings - The belief that lower blood lipid levels are always better is incorrect; cholesterol is essential for cell membranes and hormone synthesis, and excessively low levels can lead to health issues [2] - There is a misconception that thin individuals do not have blood lipid issues; however, blood lipid levels are influenced by genetics, metabolism, diet, and exercise, not just body weight [3] - High blood lipid levels are not solely an "elderly disease"; there is a rising trend of high blood lipid cases among younger populations due to unhealthy lifestyles [4] - The idea that avoiding meat guarantees low blood lipid levels is misleading; high carbohydrate and sugary foods can also elevate blood lipid levels, and cholesterol from diet only accounts for 20% of total cholesterol [5] - Many individuals believe that the absence of symptoms means no treatment is necessary; however, high blood lipid levels can silently damage blood vessels, leading to serious health risks [6] - The assumption that a lab report without arrows indicates normal levels is flawed; individual assessments are necessary for accurate health evaluations [8] - Some patients think that taking lipid-lowering medication allows them to disregard dietary and lifestyle changes; however, medication should be complemented with healthy habits for effective management [9] - The belief that once blood lipid levels are lowered, medication can be stopped is dangerous; many patients require long-term medication to maintain healthy levels and prevent rebound effects [10]

Core Viewpoint - The increasing levels of blood lipids and the prevalence of dyslipidemia among Chinese individuals highlight the need for better management of low-density lipoprotein cholesterol (LDL-C) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) [1][2][3] Group 1: Importance of LDL-C Management - LDL-C is identified as a major contributor to high blood lipids and a significant risk factor for ASCVD, emphasizing the importance of lowering LDL-C levels to reduce morbidity and mortality associated with cardiovascular diseases [1][2] - Experts advocate for a targeted and stratified approach to blood lipid management, stressing the need for public awareness and education regarding the significance of monitoring LDL-C levels [1][2] Group 2: Lifestyle and Treatment Recommendations - Lifestyle modifications, including dietary control and physical activity, are crucial as approximately two-thirds of LDL-C comes from external sources [2][3] - Regular monitoring and risk assessment of LDL-C levels are essential, especially for high-risk populations, who may require more stringent control and treatment of underlying conditions like hypertension and diabetes [2][3] Group 3: Misconceptions and Long-term Treatment - There is a prevalent misconception among patients that achieving target LDL-C levels means discontinuing medication, which can lead to adverse cardiovascular events [3][4] - Continuous and scientifically guided lipid-lowering therapy is vital for stabilizing LDL-C levels and preventing cardiovascular incidents, particularly in patients with existing ASCVD [3][4] Group 4: Current Treatment Landscape - The treatment rates and achievement rates for lipid-lowering therapy among ASCVD patients need improvement, with many still relying on traditional statin medications [4] - While statins are effective, some patients may have contraindications, necessitating the use of non-statin alternatives for optimal LDL-C management [4]